Mabworks Biotech Overview
- Year Founded
-
2003
- Status
-
IPO Registration
- Employees
-
283
- Latest Deal Type
-
IPO
- (Announced)
- Investors
-
27
Mabworks Biotech General Information
Description
Developer of antibody based biopharmaceutical therapies intended for autoimmune disease and oncology industry. The company's offerings include monoclonal antibody drugs, multispecific antibody therapies, long acting antibody formulations, ADCC enhanced antibodies and antibody discovery, enabling differentiated, effective and accessible treatments for patients with unmet medical needs.
Contact Information
Website
www.mab-works.comCorporate Office
- Room 2505, Building T1, Dazhu Plaza
- No. 2 Ronghua South Road
- Beijing, 100176
- China
Corporate Office
- Room 2505, Building T1, Dazhu Plaza
- No. 2 Ronghua South Road
- Beijing, 100176
- China
Mabworks Biotech Timeline
Mabworks Biotech Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 21. IPO | 04-Nov-2024 | Announced | Profitable | |||
| 20. PE Growth/Expansion | Completed | Profitable | ||||
| 19. Later Stage VC | 06-Mar-2024 | Completed | Profitable | |||
| 18. Later Stage VC | 22-Aug-2023 | Completed | Profitable | |||
| 17. IPO | 07-Mar-2023 | Completed | Profitable | |||
| 16. Later Stage VC | 05-Sep-2021 | Completed | Profitable | |||
| 15. Later Stage VC | 29-Jun-2021 | Completed | Profitable | |||
| 14. IPO | 29-Mar-2021 | Cancelled | Generating Revenue | |||
| 13. Secondary Transaction - Private | 20-Feb-2020 | $52.1M | $231M | Completed | Generating Revenue | |
| 12. Later Stage VC (Series C) | 20-Feb-2020 | $162M | $231M | Completed | Generating Revenue |
Mabworks Biotech Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | ||||||||
| Ordinary Shares | ||||||||
| Ordinary Shares | ||||||||
| Ordinary Shares | 7,879,127 | $4.06 | $4.06 | 1x | $4.06 | 11.07% | ||
| Ordinary Shares | 18,124,135 | $0.31 | $0.31 | 1x | $0.31 | 25.47% |
Mabworks Biotech Comparisons
Industry
Financing
Details
Mabworks Biotech Competitors (19)
One of Mabworks Biotech’s 19 competitors is CytomX Therapeutics, a Formerly VC-backed company based in South San Francisco, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| CytomX Therapeutics | Formerly VC-backed | South San Francisco, CA | ||||
| BioNTech | Formerly VC-backed | Mainz, Germany | ||||
| Sarepta Therapeutics | Formerly VC-backed | Cambridge, MA | ||||
| CureGenetics | Venture Capital-Backed | Suzhou, China | ||||
| Prothena | Corporation | Dublin, Ireland |
Mabworks Biotech Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Mabworks Biotech Patents
Mabworks Biotech Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026123279-A1 | Antibody binding to dll3 and use thereof | Pending | 12-Dec-2024 | ||
| WO-2026102693-A1 | Pcsk9 antibody and use thereof | Pending | 15-Nov-2024 | ||
| WO-2026091090-A1 | Antibody binding to april and use thereof | Pending | 01-Nov-2024 | ||
| WO-2026091825-A1 | Use of anti-cd3/cd20 bispecific antibody in preparation of drug for treating cd20 positive b-nhl | Pending | 30-Oct-2024 | ||
| US-20260242437-A1 | Il-2 variants and uses thereof | Pending | 09-Mar-2023 | C07K14/55 |
Mabworks Biotech Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Mabworks Biotech Investors (27)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Beijing Shengshi Hongming Investment Fund Management | Fund of Funds | Minority | ||
| Jiangsu Hengrui Medicine | Corporation | Minority | ||
| Hangzhou Tigermed Consulting Company | Corporation | Minority | ||
| Lesso Technology | Corporation | Minority | ||
| Ally Bridge Group | Growth/Expansion | Minority |
Mabworks Biotech Investments (1)
Mabworks Biotech’s most recent deal was a Later Stage VC with Duoning Biotechnology for . The deal was made on 18-Jul-2018.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Duoning Biotechnology | 18-Jul-2018 | Later Stage VC | Medical Supplies |
Mabworks Biotech FAQs
-
When was Mabworks Biotech founded?
Mabworks Biotech was founded in 2003.
-
Where is Mabworks Biotech headquartered?
Mabworks Biotech is headquartered in Beijing, China.
-
What is the size of Mabworks Biotech?
Mabworks Biotech has 283 total employees.
-
What industry is Mabworks Biotech in?
Mabworks Biotech’s primary industry is Drug Discovery.
-
Is Mabworks Biotech a private or public company?
Mabworks Biotech is a Private company.
-
What is Mabworks Biotech’s current revenue?
The current revenue for Mabworks Biotech is .
-
How much funding has Mabworks Biotech raised over time?
Mabworks Biotech has raised $333M.
-
Who are Mabworks Biotech’s investors?
Beijing Shengshi Hongming Investment Fund Management, Jiangsu Hengrui Medicine, Hangzhou Tigermed Consulting Company, Lesso Technology, and Ally Bridge Group are 5 of 27 investors who have invested in Mabworks Biotech.
-
Who are Mabworks Biotech’s competitors?
CytomX Therapeutics, BioNTech, Sarepta Therapeutics, CureGenetics, and Prothena are some of the 19 competitors of Mabworks Biotech.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
